Quantitative SPECT for dosimetry of 131I molecular radiotherapy

131I分子放射治疗剂量定量SPECT

基本信息

批准号：
ST/M007847/1
负责人：
Laura Joanne Harkness-Brennan
金额：
$ 30.33万
依托单位：
University of Liverpool
依托单位国家：
英国
项目类别：
Research Grant
财政年份：
2015
资助国家：
英国
起止时间：
2015 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=ST%2FM007847%2F1
关键词：
Quantitative SPECT dosimetry 131I molecular

项目摘要

Radiotherapy plays an essential role in cancer treatment. There are various types of therapy that are used to target differing organs and cancers. One such type is Molecular radiotherapy (MRT). In this treatment, patients are administered with a radioactive solution, which has been specifically chosen to travel to the cancerous tissue. The radioactive solution emits radiation, which damages the cancerous cells in the tissue, with little damage to the surrounding healthy tissue. The most common use of MRT is for treatment of thyroid cancer and radioimmunotherapy, however it is not possible to provide personalised treatment plans to the level of traditional radiotherapy techniques. It is also not possible to measure the radiation dose delivered to the patient during the treatment, which means that knowledge of the impact of the treatment is limited.This research aims to develop an imaging system that can be used to assess the radiation dose delivered to the patient. It is based on traditional radiation imaging techniques used in hospitals but is tailored specifically for molecular radiotherapy of the thyroid. The research will lead to personalised treatment planning, which will reduce treatment costs and potentially increase rates of successful cancer treatment. Experts from the University of Liverpool and leading clinicians at the Royal Marsden and Royal Liverpool University Hospitals will conduct the research.

放射治疗在癌症治疗中起着至关重要的作用。有多种类型的疗法用于针对不同的器官和癌症。其中一种类型是分子放射治疗（MRT）。在这种治疗中，患者会接受经过专门选择的放射性溶液，以到达癌组织。放射性溶液发出辐射，损害组织中的癌细胞，而对周围的健康组织几乎没有损害。 MRT最常见的用途是治疗甲状腺癌和放射免疫治疗，但不可能提供传统放射治疗技术水平的个性化治疗计划。也不可能测量治疗期间传递给患者的辐射剂量，这意味着对治疗影响的了解是有限的。本研究旨在开发一种成像系统，可用于评估传递给患者的辐射剂量。病人。它基于医院使用的传统放射成像技术，但专为甲状腺分子放射治疗而定制。该研究将导致个性化治疗计划，这将降低治疗成本并可能提高癌症治疗的成功率。来自利物浦大学的专家以及皇家马斯登和皇家利物浦大学医院的顶尖临床医生将进行这项研究。